Quantiferon-Cytomegalovirus assay: A potentially useful tool in the evaluation of CMV-specific CD8+ T-cell reconstitution in pediatric hematopoietic stem cell transplant patients.

Autor: Paouri B; Second Department of Pediatrics, National and Kapodistrian University of Athens, P.& A. Kyriakou Children's Hospital, Athens, Greece., Soldatou A; Second Department of Pediatrics, National and Kapodistrian University of Athens, P.& A. Kyriakou Children's Hospital, Athens, Greece., Petrakou E; Stem Cell Transplant Unit, Aghia Sophia Children's Hospital, Athens, Greece., Theodosaki M; Stem Cell Transplant Unit, Aghia Sophia Children's Hospital, Athens, Greece., Tsentidis C; Second Department of Pediatrics, National and Kapodistrian University of Athens, P.& A. Kyriakou Children's Hospital, Athens, Greece., Kaisari K; Stem Cell Transplant Unit, Aghia Sophia Children's Hospital, Athens, Greece., Oikonomopoulou C; Stem Cell Transplant Unit, Aghia Sophia Children's Hospital, Athens, Greece., Matsas M; Department of Microbiology & Serology, P. & A. Kyriakou Children's Hospital, Athens, Greece., Goussetis E; Stem Cell Transplant Unit, Aghia Sophia Children's Hospital, Athens, Greece.
Jazyk: angličtina
Zdroj: Pediatric transplantation [Pediatr Transplant] 2018 Aug; Vol. 22 (5), pp. e13220. Date of Electronic Publication: 2018 May 18.
DOI: 10.1111/petr.13220
Abstrakt: Pediatric HSCT recipients are at high risk for CMV reactivation due to their immature immune system and therapy following transplantation. Reconstitution of CMV-specific T-cell immunity is associated with control and protection against CMV. The clinical utility of monitoring CMV-specific CMI to predict CMV viremia in pediatric HSCT patients using the Quantiferon-CMV (QIAGEN ® ) test was investigated prospectively. Thirty-seven pediatric allogeneic HSCT recipients were enrolled from 3/2010-6/2012. CMV viremia was detected via weekly real-time PCR. The Quantiferon-CMV test was conducted pretransplant, early after transplantation, 30, 90, 180, 270, and 360 days post-transplantation. The incidence of CMV viremia was 51% (19/37) with half of the episodes within ≤30 days post-transplant. Fifteen patients showed CMV-specific immunity (average of 82 days). The cumulative incidence of CMV reactivation in patients who developed CMV-specific immunity was lower than those who did not (15% vs 53%; P = .023). The ROC statistical analysis showed that the AUC was 0.725 in predicting viremia, for Quantiferon-CMV test. In this cohort, the Quantiferon-CMV assay was a valuable method for identifying pediatric HSCT patients at high risk for CMV viremia, suggesting potential clinical utility to individualize patient's management post-transplant.
(© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje